AI and Human Interactions for Psoriasis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how people with psoriasis feel about interacting with an AI doctor compared to a human doctor. The goal is to determine if AI interactions can improve trust, comfort, and medication adherence. Participants will be divided into groups: one will have weekly video calls with an AI doctor, another with a human doctor, and the last will follow standard care. Ideal participants are U.S. residents with psoriasis who can use a smartphone for video calls. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could enhance future healthcare experiences.
What prior data suggests that AIGPP video interactions are safe for psoriasis patients?
Research on AI-generated automated physician providers (AIGPP) in healthcare, particularly for psoriasis, remains in its early stages. As a result, limited information exists about how people feel when interacting with AI in these settings. However, some studies have explored patients' comfort and trust levels with AI in medical environments. These studies aim to determine if AI can improve patients' adherence to treatment plans.
Regarding safety, this trial does not test a new drug or medical procedure but focuses on using AI for video calls. Since video calls do not pose a direct health risk, the main focus is on participants' experiences and adherence to treatment plans. No major negative effects have been reported from using AIGPP in this manner.
The trial also involves betamethasone dipropionate cream, a common psoriasis treatment. The FDA has approved this cream, confirming its safety when used correctly. While the AI component is new, the cream itself is well-researched and considered safe.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores innovative ways to manage psoriasis using both AI and human interactions. The AI intervention group introduces a cutting-edge approach where participants receive virtual consultations with an AI-generated physician, potentially providing more consistent monitoring and support than traditional care. Meanwhile, the human intervention group offers a personalized touch with weekly video calls from study staff, which could enhance patient engagement and adherence. This trial aims to determine whether these new methods can improve treatment outcomes and patient satisfaction compared to the standard practice of using topical betamethasone dipropionate cream with minimal follow-up.
What evidence suggests that this trial's treatments could be effective for psoriasis?
This trial will compare different approaches to managing psoriasis, including an AI intervention group. Research has shown that AI-powered virtual doctors can greatly assist in managing psoriasis. Studies have found that these AI systems predict treatment effectiveness with high accuracy, often exceeding 84%. This capability allows them to effectively anticipate treatment success. Additionally, AI tools have improved the assessment of psoriasis severity by about 33.2% compared to experienced dermatologists. These systems also predict treatment outcomes accurately, with an error rate of less than 18%. This makes AI a promising partner in better managing psoriasis symptoms.24678
Who Is on the Research Team?
Steven R Feldman, M.D., Ph.D.
Principal Investigator
Wake Forest University Health Sciences
Are You a Good Fit for This Trial?
This trial is for individuals with psoriasis who are willing to be monitored for medication adherence. Participants will either interact weekly with an AI-generated physician provider via video, receive weekly human video calls, or follow standard care.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to receive betamethasone dipropionate cream with either weekly AI-generated video interactions, weekly human video calls, or standard care with a single follow-up visit after 4 weeks
Follow-up
Participants are monitored for safety, adherence, and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AIGPP
Trial Overview
The study tests if AI interactions can influence patient attitudes and improve medication adherence in psoriasis treatment compared to human interactions or standard care. Adherence is tracked using a special cap on the medication container.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Subjects will receive BD and scheduled for a single follow up visit in 4 weeks
Subjects will receive BD and receive weekly video calls from study staff
Subject will receive with topical betamethasone dipropionate cream (BD) and have a weekly virtual visit with an AI-generated automated physician provider (AIGPP).
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor
Citations
NCT07391423 | Assessing Psoriasis Treatment Outcomes
To evaluate medication adherence over a 4-week period in patients with psoriasis randomized to weekly AI-generated automated physician providers (AIGPP) video ...
Assessing Psoriasis Treatment Outcomes - ClinicalTrials.Veeva
To evaluate medication adherence over a 4-week period in patients with psoriasis randomized to weekly AI-generated automated physician providers ...
Insights into the Impact of Artificial Intelligence on Psoriasis ...
AI-driven models demonstrate significant clinical utility with phototherapy outcome prediction, achieving high sensitivity (>84%) and accuracy ( ...
(PDF) Multimodal Artificial Intelligence Models for Psoriasis ...
Automated PASI scoring models show a 33.2% enhancement compared to 43 seasoned dermatologists (mean absolute error 3.12 versus 4.67). Genuine ...
Artificial Intelligence and Psoriatic Disease
Treatment outcomes were predicted with high accuracy and less than 18% classification error, with data that are routinely available to ...
NCT07391423 | Assessing Psoriasis Treatment Outcomes
Another primary outcome will be psoriasis patients' attitudes, trust, and comfort levels with AIGPP interactions in a healthcare setting, which will be ...
7.
htsyndication.com
htsyndication.com/health-daily-digest/article/clinical-trial%3A-assessing-psoriasis-treatment-outcomes/97324757Clinical Trial: Assessing Psoriasis Treatment Outcomes
To evaluate medication adherence over a 4-week period in patients with psoriasis randomized to weekly AI-generated automated physician providers ...
Emerging Uses of Artificial Intelligence in Chronic ... - PMC
This scoping review aimed to assess the emerging applications of AI use in the context of chronic, non-neoplastic dermatologic diseases.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.